Anti-TNF therapy for paediatric IBD: The Scottish national experience

Archives of Disease in Childhood

Volumn 100, Issue 4, 2015, Pages 399-405

  Cameron, F L ^a   Wilson, M L ^a   Basheer, N ^a   Jamison, A ^b   McGrogan, P ^c   Bisset, W M ^d   Gillett, P M ^e   Russell, R K ^c   Wilson, David C ^a,e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; BACTERIAL ARTHRITIS; CHICKENPOX; CHILD; CHILDHOOD DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COUGHING; CROHN DISEASE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARDRUM PERFORATION; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMPETIGO; INFECTION; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; LEUKOPENIA; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NEUTROPENIA; NIGHT SWEAT; PARONYCHIA; PERIANAL ABSCESS; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RECTUM DISEASE; REMISSION; SCHOOL CHILD; SCOTSMAN; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIRUS INFECTION; CLINICAL TRIAL; COLITIS, ULCERATIVE; DRUG COMBINATION; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; SCOTLAND; TREATMENT OUTCOME;

EID: 84924961778     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-305812     Document Type: Article

References (33)

1. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22.
2. Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis 2011;18:999-1005.
3. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Br Med J 2003;88:995-1000.
4. Physicians RCo. Biological therapies audit sub group. National clinical audit report of biological therapies. Paediatric national report. UK IBD audit. London: Royal College of Physicians, 2013.
5. Zamvar V, Sugarman ID, Tawfik RF, et al. Posterior reversible encephalopathy syndrome following infliximab infusion. J Pediatr Gastroenterol Nutr 2009;48:102-5.
6. Haddock R, Garrick V, Horrocks I, et al. A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with Infliximab. J Crohn's Colitis 2011;5:623-7.
7. Mackey AC, Green L, Liang L, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
8. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012;18:985-1002.
9. National Institute for Clinical E. Guidance on the use of infliximab for Crohn's disease. NICE 2002(1):40.
10. Nice. Infliximab (review) and adalimumab for the treatment of Crohn's disease. NICE technology appraisal guidance 187 2010.
11. Wilson DC, Thomas AG, Croft NM, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010;50:S14-34.
12. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
13. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate-to-severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391-9.
14. Ruemmele FM, Lachaux A, Cézard JP, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009;15:388-94.
15. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
17. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial. Gastroenterology 2006;130:323-33.
18. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
19. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab a randomized trial. Ann Intern Med 2007;146:829-38.
20. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
21. McDermott E, Murphy S, Keegan D, et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohn's Colitis 2013;7:150-3.
22. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365-74. e2.
23. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:946-53.
24. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5-36.
25. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-9.
26. De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011;33:243-50.
27. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
28. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
29. Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:40-5.
30. de Ridder L, Benninga MA, Taminiau JAJM, et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14.
31. Crombé V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011;17:2144-52.
32. Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1177-86.
33. Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohn's Colitis 2013;7:369-76.